172 related articles for article (PubMed ID: 29222271)
1. Optimizing therapy for mantle cell lymphoma.
Martin P
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):304-309. PubMed ID: 29222271
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
3. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
[TBL] [Abstract][Full Text] [Related]
4. Evolving treatment strategies in mantle cell lymphoma.
Edwin NC; Kahl B
Best Pract Res Clin Haematol; 2018 Sep; 31(3):270-278. PubMed ID: 30213396
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
McCulloch R; Visco C; Eyre TA; Frewin R; Phillips N; Tucker DL; Quaglia FM; McMillan A; Lambert J; Crosbie N; Rule S
Br J Haematol; 2020 May; 189(4):684-688. PubMed ID: 32011729
[TBL] [Abstract][Full Text] [Related]
6. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
[TBL] [Abstract][Full Text] [Related]
7. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Prescrire Int; 2016 Apr; 25(170):91. PubMed ID: 27186618
[No Abstract] [Full Text] [Related]
9. [Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].
Du KX; Shen HR; Wang L; Liang JH; Wu JZ; Li Y; Xia Y; Yin H; Li JY; Xu W
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):333-336. PubMed ID: 37357004
[No Abstract] [Full Text] [Related]
10. Bilateral Infiltrative Optic Neuropathy of Systemic Mantle Cell Lymphoma.
Aldrees S; Jeeva-Patel T; Margolin E
Can J Neurol Sci; 2020 May; 47(3):428-430. PubMed ID: 32046809
[No Abstract] [Full Text] [Related]
11. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
Armand P; Redd R; Bsat J; Mayuram S; Giardino A; Fisher DC; LaCasce AS; Jacobson C; Davids MS; Brown JR; Weng L; Wilkins J; Faham M; Freedman AS; Joyce R; Jacobsen ED
Br J Haematol; 2016 Apr; 173(1):89-95. PubMed ID: 26729345
[TBL] [Abstract][Full Text] [Related]
13. Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report.
Ettleson M; Bongers KS; Vitale K; Perissinotti AJ; Phillips T; Marini BL
J Oncol Pharm Pract; 2019 Apr; 25(3):731-734. PubMed ID: 29385883
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
[TBL] [Abstract][Full Text] [Related]
15. Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.
Kawaguchi Y; Nakamaki T; Abe M; Baba Y; Murai S; Watanuki M; Arai N; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Harada H; Saito B
Acta Haematol; 2018; 139(1):12-18. PubMed ID: 29301121
[TBL] [Abstract][Full Text] [Related]
16. Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma.
Schalk E; Jentsch-Ullrich K
Ann Hematol; 2023 Jun; 102(6):1617-1620. PubMed ID: 36928308
[No Abstract] [Full Text] [Related]
17. [Mantle Cell Lymphoma - Cutting edge Dia-gnostics and Treatment Approaches].
Klener P; Trněný M
Klin Onkol; 2015; 28 Suppl 3():3S80-6. PubMed ID: 26489506
[TBL] [Abstract][Full Text] [Related]
18. Indolent T cell lymphoma involving the central nervous system and successfully treated by bendamustine.
Hui M; Chen M
Ann Hematol; 2022 Apr; 101(4):911-913. PubMed ID: 34487230
[No Abstract] [Full Text] [Related]
19. Palatine Tonsils Primary Presentation of Blastoid Variant of Mantle Cell Lymphoma: Case Report.
Marques JAS; Ferreira F; Melo DP; Santos M; Vaz RP
Head Neck Pathol; 2021 Jun; 15(2):588-592. PubMed ID: 33091144
[TBL] [Abstract][Full Text] [Related]
20. Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma.
Khodarahmi I; Ghesani N
Blood; 2017 Aug; 130(9):1174. PubMed ID: 28860327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
